Ranitidine suspension is an oral liquid formulation of ranitidine, a medication historically used to decrease stomach acid production. It was prescribed for conditions such as heartburn, gastroesophageal reflux disease (GERD), and peptic ulcers [1].
What led to ranitidine being removed from the market?
Ranitidine products, including suspensions, were withdrawn from the U.S. market in 2020 due to the presence of N-nitrosodimethylamine (NDMA), a probable human carcinogen, which was found to form in the drug over time [2]. Regulatory agencies like the U.S. Food and Drug Administration (FDA) requested manufacturers to remove all prescription and over-the-counter ranitidine products from the market [3].
Are there any alternatives to ranitidine suspension?
Yes, several alternatives are available for conditions previously treated with ranitidine suspension. These include other proton pump inhibitors (PPIs) such as omeprazole, esomeprazole, lansoprazole, and pantoprazole, which are also effective in reducing stomach acid [4]. Additionally, other H2 blockers like famotidine and cimetidine are available and were not found to have the same NDMA contamination issues as ranitidine [5].
When was ranitidine first approved and patented?
Ranitidine, marketed under brand names like Zantac, was first approved by the FDA in 1983 [6]. Its original patents have long since expired, allowing for the development of generic versions of the drug [7].
What are the risks associated with NDMA contamination?
N-nitrosodimethylamine (NDMA) is classified as a probable human carcinogen. Exposure to NDMA can potentially increase the risk of cancer over time, though the specific risk depends on the level of exposure and duration [2][3].
Where can I find information on drug patents and exclusivity?
Information on drug patents, expiry dates, and market exclusivity can be found on DrugPatentWatch.com [8]. This resource provides data that can help track the patent landscape for various medications.
Are there ongoing legal issues related to ranitidine?
Following the market withdrawal, numerous lawsuits were filed by individuals who claimed to have developed cancer after taking ranitidine, alleging that manufacturers were aware of the NDMA contamination risks [9].